These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 33917118)

  • 1. An In Vivo Predictive Dissolution Methodology (iPD Methodology) with a BCS Class IIb Drug Can Predict the In Vivo Bioequivalence Results: Etoricoxib Products.
    Gonzalez-Alvarez I; Bermejo M; Tsume Y; Ruiz-Picazo A; Gonzalez-Alvarez M; Hens B; Garcia-Arieta A; Amidon GE; Amidon GL
    Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33917118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
    Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
    Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of supersaturation level for oral absorption of BCS class IIb drugs, dipyridamole and ketoconazole, using in vivo predictive dissolution system: Gastrointestinal Simulator (GIS).
    Tsume Y; Matsui K; Searls AL; Takeuchi S; Amidon GE; Sun D; Amidon GL
    Eur J Pharm Sci; 2017 May; 102():126-139. PubMed ID: 28263914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Vitro Dissolution of Fluconazole and Dipyridamole in Gastrointestinal Simulator (GIS), Predicting in Vivo Dissolution and Drug-Drug Interaction Caused by Acid-Reducing Agents.
    Matsui K; Tsume Y; Amidon GE; Amidon GL
    Mol Pharm; 2015 Jul; 12(7):2418-28. PubMed ID: 25985298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving Dissolution Behavior and Oral Absorption of Drugs with pH-Dependent Solubility Using pH Modifiers: A Physiologically Realistic Mass Transport Analysis.
    Salehi N; Kuminek G; Al-Gousous J; Sperry DC; Greenwood DE; Waltz NM; Amidon GL; Ziff RM; Amidon GE
    Mol Pharm; 2021 Sep; 18(9):3326-3341. PubMed ID: 34428047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Vivo Predictive Dissolution and Biopharmaceutic-Based In Silico Model to Explain Bioequivalence Results of Valsartan, a Biopharmaceutics Classification System Class IV Drug.
    Gonzalez-Alvarez I; Ruiz-Picazo A; Selles-Talavera R; Figueroa-Campos A; Merino V; Bermejo M; Gonzalez-Alvarez M
    Pharmaceutics; 2024 Mar; 16(3):. PubMed ID: 38543284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilization of Gastrointestinal Simulator, an in Vivo Predictive Dissolution Methodology, Coupled with Computational Approach To Forecast Oral Absorption of Dipyridamole.
    Matsui K; Tsume Y; Takeuchi S; Searls A; Amidon GL
    Mol Pharm; 2017 Apr; 14(4):1181-1189. PubMed ID: 28231003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Combination of GIS and Biphasic to Better Predict In Vivo Dissolution of BCS Class IIb Drugs, Ketoconazole and Raloxifene.
    Tsume Y; Igawa N; Drelich AJ; Amidon GE; Amidon GL
    J Pharm Sci; 2018 Jan; 107(1):307-316. PubMed ID: 28919384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a three compartment in vitro gastrointestinal simulator dissolution apparatus to predict in vivo dissolution.
    Takeuchi S; Tsume Y; Amidon GE; Amidon GL
    J Pharm Sci; 2014 Nov; 103(11):3416-3422. PubMed ID: 25251982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Introduction of a New Flexible In Vivo Predictive Dissolution Apparatus, GIS-Alpha (GIS-α), to Study Dissolution Profiles of BCS Class IIb Drugs, Dipyridamole and Ketoconazole.
    Tsume Y; Patel S; Wang M; Hermans A; Kesisoglou F
    J Pharm Sci; 2020 Nov; 109(11):3471-3479. PubMed ID: 32888960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Evaluation of In Vitro Drug Dissolution of Commercially Available Oral Dosage Forms for Itraconazole in Gastrointestinal Simulator With Biorelevant Media.
    Matsui K; Tsume Y; Amidon GE; Amidon GL
    J Pharm Sci; 2016 Sep; 105(9):2804-2814. PubMed ID: 27020985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Gastrointestinal Simulator, Mass Transport Analysis, and Absorption Simulation to Investigate the Impact of pH Modifiers in Mitigating Weakly Basic Drugs' Performance Issues Related to Gastric pH: Palbociclib Case Study.
    Kuminek G; Salehi N; Waltz NM; Sperry DC; Greenwood DE; Hate SS; Amidon GE
    Mol Pharm; 2023 Jan; 20(1):147-158. PubMed ID: 36367432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Vitro Dissolution as a Tool for Formulation Selection: Telmisartan Two-Step IVIVC.
    Ruiz Picazo A; Martinez-Martinez MT; Colón-Useche S; Iriarte R; Sánchez-Dengra B; González-Álvarez M; García-Arieta A; González-Álvarez I; Bermejo M
    Mol Pharm; 2018 Jun; 15(6):2307-2315. PubMed ID: 29746133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Vitro, in Silico, and in Vivo Assessments of Intestinal Precipitation and Its Impact on Bioavailability of a BCS Class 2 Basic Compound.
    Kou D; Zhang C; Yiu H; Ng T; Lubach JW; Janson M; Mao C; Durk M; Chinn L; Winter H; Wigman L; Yehl P
    Mol Pharm; 2018 Apr; 15(4):1607-1617. PubMed ID: 29522347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.
    Jantratid E; Prakongpan S; Amidon GL; Dressman JB
    Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The biowaiver extension for BCS class III drugs: the effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation.
    Tsume Y; Amidon GL
    Mol Pharm; 2010 Aug; 7(4):1235-43. PubMed ID: 20557130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigating the Discriminatory Power of BCS-Biowaiver in Vitro Methodology to Detect Bioavailability Differences between Immediate Release Products Containing a Class I Drug.
    Colón-Useche S; González-Álvarez I; Mangas-Sanjuan V; González-Álvarez M; Pastoriza P; Molina-Martínez I; Bermejo M; García-Arieta A
    Mol Pharm; 2015 Sep; 12(9):3167-74. PubMed ID: 26287948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Candesartan Cilexetil In Vitro-In Vivo Correlation: Predictive Dissolution as a Development Tool.
    Figueroa-Campos A; Sánchez-Dengra B; Merino V; Dahan A; González-Álvarez I; García-Arieta A; González-Álvarez M; Bermejo M
    Pharmaceutics; 2020 Jul; 12(7):. PubMed ID: 32640620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computer simulations using GastroPlus to justify a biowaiver for etoricoxib solid oral drug products.
    Okumu A; DiMaso M; Löbenberg R
    Eur J Pharm Biopharm; 2009 May; 72(1):91-8. PubMed ID: 19056493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.